Found: 87
Select item for more details and to access through your institution.
Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home.
- Published in:
- Journal of Pharmacy Practice, 2022, v. 35, n. 6, p. 827, doi. 10.1177/08971900211000682
- By:
- Publication type:
- Article
Inflammatory bowel disease: past, present, and future.
- Published in:
- Journal of Gastroenterology, 2007, v. 42, n. 1, p. 16, doi. 10.1007/s00535-006-1995-7
- By:
- Publication type:
- Article
Correction to: Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Review article: Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 11, p. 1216, doi. 10.1111/apt.17498
- By:
- Publication type:
- Article
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 2, p. 205, doi. 10.1111/apt.17286
- By:
- Publication type:
- Article
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 12, p. 1534, doi. 10.1111/apt.16848
- By:
- Publication type:
- Article
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 11, p. 1442, doi. 10.1111/apt.16626
- By:
- Publication type:
- Article
Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 2, p. 281, doi. 10.1111/apt.16136
- By:
- Publication type:
- Article
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 11/12, p. 1658, doi. 10.1111/apt.16119
- By:
- Publication type:
- Article
Long‐term safety of vedolizumab for inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 8, p. 1353, doi. 10.1111/apt.16060
- By:
- Publication type:
- Article
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 4, p. 669, doi. 10.1111/apt.15921
- By:
- Publication type:
- Article
Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1.
- Published in:
- Clinical & Experimental Gastroenterology, 2020, v. 13, p. 211, doi. 10.2147/CEG.S248597
- By:
- Publication type:
- Article
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
- Published in:
- Digestive Diseases, 2017, v. 35, n. 1/2, p. 13, doi. 10.1159/000449077
- By:
- Publication type:
- Article
New Drugs on the Horizon for IBD.
- Published in:
- Digestive Diseases, 2014, v. 32, p. 74, doi. 10.1159/000367832
- By:
- Publication type:
- Article
The Risks and Benefits of Early Immunosuppression and Biological Therapy.
- Published in:
- Digestive Diseases, 2013, v. 30, p. 100, doi. 10.1159/000342731
- By:
- Publication type:
- Article
The Risks and Benefits of Early Immunosuppression and Biological Therapy.
- Published in:
- Digestive Diseases, 2012, v. 30, p. 100, doi. 10.1159/000342731
- By:
- Publication type:
- Article
The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease.
- Published in:
- Digestive Diseases, 2010, v. 27, p. 68, doi. 10.1159/000268123
- By:
- Publication type:
- Article
Effects of Growth Hormone Secretion on Body Composition in Patients with Crohn’s Disease.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2003, v. 88, n. 11, p. 5468, doi. 10.1210/jc.2003-030608
- By:
- Publication type:
- Article
Remote Short Sessions of Heart Rate Variability Biofeedback Monitored With Wearable Technology: Open-Label Prospective Feasibility Study.
- Published in:
- JMIR Mental Health, 2024, v. 11, p. 1, doi. 10.2196/55552
- By:
- Publication type:
- Article
Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy.
- Published in:
- Patient, 2022, v. 15, n. 3, p. 353, doi. 10.1007/s40271-021-00561-9
- By:
- Publication type:
- Article
Factors Associated with Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
- Published in:
- Genome Biology, 2012, v. 13, n. 9, p. r79, doi. 10.1186/gb-2012-13-9-r79
- By:
- Publication type:
- Article
Positioning Sphingosine-1 Phosphate Receptor Modulators in Inflammatory Bowel Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 7, p. 417
- By:
- Publication type:
- Article
Comparative Effectiveness Research in Inflammatory Bowel Disease: The VARSITY Study and Beyond.
- Published in:
- Gastroenterology & Hepatology, 2019, v. 15, n. 12, p. 682
- By:
- Publication type:
- Article
Inhibition of Interleukin-12 and/or -23 for the Treatment of Inflammatory Bowel Disease.
- Published in:
- 2016
- By:
- Publication type:
- Interview
Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis.
- Published in:
- Digestive Diseases & Sciences, 2023, v. 68, n. 9, p. 3702, doi. 10.1007/s10620-023-08014-z
- By:
- Publication type:
- Article
Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study.
- Published in:
- Digestive Diseases & Sciences, 2021, v. 66, n. 6, p. 1836, doi. 10.1007/s10620-020-06493-y
- By:
- Publication type:
- Article
The Whys and Hows of Fourth-Year Inflammatory Bowel Disease Fellowships.
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1418, doi. 10.1002/cpt.3235
- By:
- Publication type:
- Article
Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Differences Between the 2016 and 2022 Food and Drug Administration Guidance—Implications for Design and Interpretation of Clinical Trials in Ulcerative Colitis.
- Published in:
- Crohn's & Colitis 360, 2024, v. 6, n. 2, p. 1, doi. 10.1093/crocol/otae038
- By:
- Publication type:
- Article
Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1.
- Published in:
- Crohn's & Colitis 360, 2024, v. 6, n. 1, p. 1, doi. 10.1093/crocol/otad076
- By:
- Publication type:
- Article
Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
- Published in:
- Crohn's & Colitis 360, 2023, v. 5, n. 4, p. 1, doi. 10.1093/crocol/otad070
- By:
- Publication type:
- Article
Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.
- Published in:
- Crohn's & Colitis 360, 2022, v. 4, n. 3, p. 1, doi. 10.1093/crocol/otac016
- By:
- Publication type:
- Article
Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD.
- Published in:
- Crohn's & Colitis 360, 2021, v. 3, n. 3, p. 1, doi. 10.1093/crocol/otab023
- By:
- Publication type:
- Article
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
- Published in:
- Journal of Patient-Reported Outcomes, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41687-023-00645-0
- By:
- Publication type:
- Article
Evaluation of Possible Inflammatory Bowel Disease: A Survey of Rhode Island Physicians.
- Published in:
- Medicine & Health Rhode Island, 2012, v. 95, n. 1, p. 4
- By:
- Publication type:
- Article
Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2006, v. 15, n. 1, p. 47, doi. 10.1002/pds.1118
- By:
- Publication type:
- Article
Lessons Learned from the Ocean State Crohn's and Colitis Area Registry.
- Published in:
- Rhode Island Medical Journal, 2022, v. 105, n. 10, p. 38
- By:
- Publication type:
- Article
Efficient augmentation and relaxation learning for individualized treatment rules using observational data.
- Published in:
- Journal of Machine Learning Research, 2019, n. 30-56, p. 1
- By:
- Publication type:
- Article
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1209, doi. 10.1111/apt.15735
- By:
- Publication type:
- Article
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 10, p. 997, doi. 10.1111/apt.15716
- By:
- Publication type:
- Article
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 2, p. 271, doi. 10.1111/apt.15555
- By:
- Publication type:
- Article
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 10, p. 1068, doi. 10.1111/apt.15514
- By:
- Publication type:
- Article
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
- Published in:
- Journal of Crohn's & Colitis, 2024, v. 18, n. 8, p. 1270, doi. 10.1093/ecco-jcc/jjae038
- By:
- Publication type:
- Article
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
- Published in:
- Journal of Crohn's & Colitis, 2024, v. 18, n. 7, p. 1091, doi. 10.1093/ecco-jcc/jjae013
- By:
- Publication type:
- Article
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.
- Published in:
- Journal of Crohn's & Colitis, 2023, v. 17, n. 12, p. 2012, doi. 10.1093/ecco-jcc/jjad112
- By:
- Publication type:
- Article